- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04430959
Candesartan as an Adjunctive Treatment for Bipolar Depression
April 19, 2022 updated by: Marsal Sanches, The University of Texas Health Science Center, Houston
A Pilot, Proof of Concept, Placebo-controlled Trial of Candesartan as an Adjunctive Treatment for Bipolar Depression
This study will assess the safety and tolerability of Candesartan when used in patients with Bipolar Disorder, in addition to their medication treatment.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Pharmacological options for the treatment of Bipolar disorder (BD) are limited and a large proportion of patients does not show adequate response to treatment, especially in the case of bipolar depression.
It has been hypothesized that dysfunctions in the renin-angiotensin system (RAS) may be involved in the pathophysiology of BD.
We propose a double-blind, randomized, placebo-controlled, cross-over, proof-of-concept trial to investigate the effects of candesartan, an angiotensin-II receptor antagonist capable to cross the blood-brain barrier, as an adjunctive agent in the treatment of bipolar depression.
Bipolar patients on a depressive episode will be randomly assigned to undergo two consecutive 4-week treatment periods with either candesartan (4 mg daily) or placebo in a crossover study.
At the beginning of each treatment period, participants will complete a resting-state functional MRI scan, to be performed 1.5 hours after the first dose of the study medication.
Subjects will be followed weekly and the Montgomery-Asberg Depression Rating Scale (MADRS) will be adopted as the primary outcome measure.
Response will be defined as a decrease equal or higher than 50% in the MADRS score from the time of study entry to the 4th week of each treatment period.
Possible associations between changes in brain connectivity (measured through resting state functional MRI) and subsequent response to treatment will also be analyzed.
Study Type
Interventional
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
A diagnosis of BD type I or II, and currently in a depressive episode, based on DSM-5 criteria.
Inclusion criteria:
- Age 18 to 65 years.
- A diagnosis of BD type I or II according to DSM-5 criteria, established through the administration of the MINI.
- Currently in a depressive episode, based on DSM-5 criteria.
- MADRS >20 at entry in the study.
- No history of hypertension, diabetes, stroke, liver, kidney, heart disease, bleeding disorders, cancer, hypothyroidism, auto-immune diseases, and any brain disorder (seizure disorder, stroke, dementia, or neurodegenerative diseases), as well as other conditions that could impact patient's safety associated with participation in the study.
- On therapeutic doses of a mood stabilizing drug (anticonvulsants or atypical antipsychotics, but not lithium) or combinations of medications (including antidepressants, as long as receiving at least one mood stabilizing agent) for at least two weeks.
- Allowed psychiatric comorbid conditions, such as anxiety disorders, PTSD and past history of substance use (as long as do NOT meet abuse or dependence criteria according to the SCID-I in the past 2 months).
Exclusion criteria:
- Current use of angiotensin receptor antagonists, angiotensin converting enzyme inhibitors. (ACE inhibitors), or a history of allergies or poor tolerability to those medications
- Current use of lithium or any other medications that could implicate in potentially dangerous. interactions with candesartan, based on available literature and the investigator's judgement.
- Pregnancy or current breastfeeding.
- Acute systemic infections or other acute medical conditions at the time of study entry.
- Acute suicidal or homicidal ideation or other imminent concerns about safety, based on the investigator's judgement and/or on a score equal or higher than 4 in the item 10 of the MADRS.
- Family history of hereditary neurologic disorder.
- Unable to give informed consent for any reason.
- Floating metallic objects in the body.
- Positive urine drug screening at the time of study entry.
- Current or previous diagnosis of intellectual disability, learning disability, or other severe neurodevelopmental disorders.
- History of traumatic brain injury or head trauma with loss of consciousness for more than 30 minutes.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Candesartan first then Placebo
4 weeks of candesartan with crossover to the other.
|
Candesartan 4 mg, tablets, orally, once daily for 4 weeks
Other Names:
Candesartan placebo-matching tablets, orally, once daily for 4 weeks
|
Placebo Comparator: Placebo first then Candesartan
4 weeks of placebo with crossover to the other.
|
Candesartan 4 mg, tablets, orally, once daily for 4 weeks
Other Names:
Candesartan placebo-matching tablets, orally, once daily for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery-Asberg Depression Rating Scale (MADRS) scores at the end of each treatment period.
Time Frame: Four weeks
|
MADRS scores range from 0-60; higher scores indicate a higher level of severity of depressive symptoms.
Response will be defined as a decrease equal or higher than 50% in the total MADRS score between the baseline and the 4th week of each treatment period.
|
Four weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Anxiety Rating Scale (HAM-A) scores at the end of each treatment period.
Time Frame: Four weeks
|
HAM-A scores range from 0-56, with higher scores indicating more severe anxiety
|
Four weeks
|
Clinical Global Impression - Severity scale (CGI-S) scores at the end of each treatment period.
Time Frame: Four weeks
|
The CGI-S is a 7-point scale used to rate the severity of the patient's illness at the time of assessment, compared to the clinician's past experience regarding patients with similar diagnosis
|
Four weeks
|
Functional Assessment Screening Tool scores at the end of each treatment period.
Time Frame: Four weeks
|
The Functional Assessment Screening Tool (FAST) identifies factors that may influence problem behaviors.
It is a self-report checklist that contains 16 items, with each questions being marked as either "yes", "no", or "not applicable".
The checklist is designed to identify whether maladaptive behavior is maintained in four domains: attention/preferred items, escape from tasks/activities, sensory stimulation, pain attenuation.
|
Four weeks
|
Young Mania Rating Scale (YMRS) at the end of each treatment period
Time Frame: Four weeks
|
The YMRS is one of the most frequently utilized rating scales to assess manic symptoms.
The scale has 11 items, based on the patient's subjective report and observations made during the clinical interview.
Higher scores indicate a greater severity of manic symptoms.
Given the cyclic nature of BD, the YMRS will be utilized to monitor patients as for the possibility of a manic switch over each four-week treatment period.
|
Four weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Marsal Sanches, MD PhD, University of Texas, Science Center at Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Anticipated)
July 1, 2022
Study Completion (Anticipated)
September 1, 2022
Study Registration Dates
First Submitted
May 11, 2020
First Submitted That Met QC Criteria
June 10, 2020
First Posted (Actual)
June 16, 2020
Study Record Updates
Last Update Posted (Actual)
April 27, 2022
Last Update Submitted That Met QC Criteria
April 19, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-19-1046
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder Depression
-
University Health Network, TorontoCompletedBipolar Disorder | Bipolar Depression | Bipolar I Depression | Bipolar II DepressionCanada
-
Forest LaboratoriesGedeon Richter Ltd.CompletedDepression, BipolarUnited States, Ukraine, Bulgaria, Canada, Colombia, Russian Federation
-
Queen's UniversityPfizer; Providence Health & Services; MDS Pharma ServicesCompletedDepression, BipolarCanada
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
NeuroRx, Inc.Prevail InfoworksAvailableBipolar Depression | Bipolar Affective Disorder
-
Ewha Womans University Mokdong HospitalWithdrawnDepression, BipolarKorea, Republic of
-
Tri-Service General HospitalCompletedDepressive Disorder, Major | Depression, Bipolar | Electricity; EffectsTaiwan
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Candesartan
-
GlaxoSmithKlineCompleted
-
AstraZenecaCompletedNon-diabetic Nephropathy With HypertensionKorea, Republic of
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedCardiovascular DiseaseIndia
-
St. Olavs HospitalUllevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaboratorsActive, not recruiting
-
TakedaCompleted
-
Huazhong University of Science and TechnologyUnknown
-
AstraZenecaTakedaCompleted
-
AstraZenecaCompleted
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyTerminatedChronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) LevelGermany, France, Netherlands